Januari 15, 2026
OncoInv collaborates with the Universidad de Costa Rica (UCR) to support the introduction of the OncoSeek® multi-cancer detection test in Costa Rica. Through this collaboration, the test is now available within a public academic and clinical setting, marking an important step in expanding access to advanced cancer detection technologies in the region.
OncoSeek® is designed to support the early detection of nine cancer types with high mortality rates by analysing the concentration of a selected set of protein tumour markers using a single blood sample. The test applies a machine learning–based approach to evaluate patterns across markers and clinical factors and is intended as a cancer detection tool for individuals with an increased risk of cancer. Its implementation at UCR takes place within an academic framework that integrates clinical expertise, research, and public health objectives.
According to Rodrigo Mora Rodríguez, Director of the Center for Research in Surgery and Cancer at the Universidad de Costa Rica, early detection remains one of the most significant challenges in cancer care.
“Detecting cancer at earlier stages allows for more effective treatment options, reduces the need for aggressive therapies, and improves patient outcomes,” he said. “By offering this test within the Universidad de Costa Rica, we can combine scientific research with clinical practice and generate valuable knowledge that supports better decision-making in cancer care.”
The test focuses on cancers that are known for their aggressive biological behaviour and are often diagnosed at advanced stages. In addition to identifying cancer-associated biomarkers, the test incorporates computational analysis to estimate the most probable tissue of origin, supporting clinicians in determining appropriate follow-up diagnostics. The test does not provide a diagnosis but is intended to guide further clinical evaluation.
Within this collaboration, OncoInv supports access to the technology and its integration within the academic and clinical environment of UCR. The collaboration emphasises careful clinical implementation and responsible use within this specific context.
By making the test available through the Universidad de Costa Rica, access to multi-cancer detection is expanded within the Costa Rican healthcare landscape. The collaboration reflects a shared commitment to supporting earlier detection of cancer and improving patient outcomes through responsible implementation of advanced technologies.
Further details about the launch are available in the announcement published by the Universidad de Costa Rica
Foto: Jenniffer Jiménez Córdoba.
